| Document |
Document Title |
|
WO/2022/094355A1 |
The present disclosure relates to a class of pyrimidine compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, stereoisomers, solvates, and hydrates thereof. The present disclosure also relates to a process of prep...
|
|
WO/2022/093748A1 |
This invention relates to processes for making bio-based renewable oils from non-food biomass sources. Such renewable oils are used for cosmetics formulations. More specifically, disclosed are processes of preparation of furan-based comp...
|
|
WO/2022/094354A1 |
The present disclosure relates to a class of pyrimidine compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, stereoisomers, solvates, and hydrates thereof. The present disclosure also relates to a process of prep...
|
|
WO/2022/080765A1 |
The present invention relates to a skin whitening composition comprising a dihydrofuran-2(3H)-one derivative having melanogenesis inhibition and melanosome decomposition activity, an isomer thereof, or a pharmaceutically acceptable salt ...
|
|
WO/2022/073969A1 |
The present invention relates to compounds of Formula (I), wherein Ar1, A, B, and R1 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceut...
|
|
WO/2022/060020A1 |
The present invention relates to a novel organic electroluminescent compound and an organic electroluminescent device using same and, more specifically, to: a compound having excellent thermal stability, electrochemical stability, light-...
|
|
WO/2022/053628A1 |
The present invention relates to a compound of formula (I). It also relates to a pharmaceutical composition comprising at least one compound of formula (I) and at least one pharmaceutically acceptable support. Finally, it relates to the ...
|
|
WO/2022/053013A1 |
Disclosed in the present invention are a compound represented by formula Ib or IIb, a cis or trans isomer, enantiomer, diastereomer, racemate, tautomer, solvate, hydrate, and pharmaceutically acceptable salt thereof, or a mixture thereof...
|
|
WO/2022/050533A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2022/050592A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, and an organic light-emitting element comprising same.
|
|
WO/2022/047014A1 |
The present disclosure relates to copper complexes, pharmaceutical compositions comprising these complexes, chemical processes for preparing these complexes, and their use in the treatment of neurodegenerative disease, e.g., amyotrophic ...
|
|
WO/2022/042299A1 |
A method for extracting mupirocin. The main steps thereof comprise: resin adsorption, desorption and concentration, multi-step extraction, and dehydration and decoloration, wherein the multi-step extraction comprises at least one ester s...
|
|
WO/2022/040788A1 |
Anti -cancer, chemotherapeutic, or antiproliferative compositions comprising, as an active ingredient, a compound of formula (I0), or a salt, or prodrug thereof: and an anti-cancer, chemotherapeutic, or antiproliferative compound (A) or ...
|
|
WO/2022/045618A1 |
Provided is a tertiary amine derivative, which effectively absorbs high-energy external light source in a UV region to minimize damage to organic materials inside an organic electroluminescent device, and thus contributes to a substantia...
|
|
WO/2022/034203A1 |
The present invention provides, inter alia, a process for producing a compound of formula (I) wherein the substituents are as defined in claim 1. The present invention further provides intermediate compounds utilised in said process, and...
|
|
WO/2022/033380A1 |
The present invention relates to the technical of medicinal chemistry, and specifically relates to a use of a 6-oxaspiro[4.5] decane derivative as an MOR receptor agonist for treating pain and pain-related disorders.
|
|
WO/2022/031735A1 |
The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods o...
|
|
WO/2022/031736A1 |
This disclosure is drawn to substituted pyridine compounds and compositions, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing a neurological diseases.
|
|
WO/2022/028507A1 |
A heterocyclic compound as represented by formula I, a preparation method therefor, a pharmaceutical composition comprising same and use thereof. The heterocyclic compound can be used as a complement factor B inhibitor, and is used for p...
|
|
WO/2022/025555A1 |
The present invention pertains to a multi-chain-type surfactant, and specifically, to a multi-chain-type epoxy emulsifier. The multi-chain-type surfactant according to the present invention is characterized in that the ratio of ethylene ...
|
|
WO/2022/025554A1 |
The present invention relates to a monoamine compound and, specifically, to a monoamine compound for synthesizing an emulsifier. The monoamine compound according to the present invention has an adjustable ratio of ethylene oxide and prop...
|
|
WO/2022/026892A1 |
Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R6, R7, R8 and n are as defined herein. Compounds of the present invention ar...
|
|
WO/2022/025508A1 |
The present invention provides: a compound represented by chemical formula 1; an organic electronic element comprising a first electrode, a second electrode, and an organic material layer between the first electrode and the second electr...
|
|
WO/2022/023353A1 |
The present application relates to substituted coumarin derivatives and their uses as fluorescent labels. These compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications.
|
|
WO/2022/015974A2 |
Testis-restricted melanoma antigen (MAGE) proteins are frequently hijacked in cancer and play a critical role in tumorigenesis. These proteins assemble with E3 ubiquitin ligases and function as substrate adaptors that direct the ubiquiti...
|
|
WO/2022/015979A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2022/010150A1 |
The present invention relates to: a novel TNF activity inhibitor compound; a pharmaceutically acceptable salt thereof; a preventing, ameliorating, or treating method comprising administering a compound according to the present invention;...
|
|
WO/2022/011083A1 |
The disclosure relates to compounds of formula I, which are formyl peptide 2 (FPR2) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart...
|
|
WO/2022/011084A1 |
The disclosure relates to compounds of Formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for e...
|
|
WO/2021/262587A1 |
The present disclosure provides compounds of Formula I or II. Compounds of Formula I or II may be used in pharmaceutical formulations, and may be used for modulating glucocorticoid receptors.
|
|
WO/2021/263203A1 |
The present invention relates to compounds and methods of inhibiting C-X-C receptor type 4 (CXCR4). The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using s...
|
|
WO/2021/261946A1 |
The present application provides a heterocyclic compound capable of greatly improving the lifespan, efficiency, electrochemical stability, and thermal stability of an organic light-emitting device, and an organic light-emitting device in...
|
|
WO/2021/256836A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, and an organic light-emitting device comprising same.
|
|
WO/2021/253095A1 |
This invention relates to compounds of formula (I) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compounds of formula (I) to treat necroptosis and/or inhibit...
|
|
WO/2021/252859A1 |
The disclosure provides at least one compound, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of formula (I), deuterated derivatives thereof, and pharmaceutically acceptable salts of any of the foregoing...
|
|
WO/2021/252849A1 |
The disclosure provides compounds of Formula (I), deuterated derivatives of those compounds, and pharmaceutically acceptable salts of those compounds and derivatives, compositions comprising the same, and methods of using the same, inclu...
|
|
WO/2021/250565A1 |
The present invention relates to an improved process for preparation of Empagliflozin of formula (I). The invention further relates to preparation of crystalline form of Empagliflozin and its particle size having coarser particle or D50 ...
|
|
WO/2021/248022A1 |
The present disclosure relates to a pharmaceutical composition, such as a dry powder inhalation formulation or an injectable formulation, comprising a mixture of an antiviral agent and a mast cell stabilizer. The present disclosure relat...
|
|
WO/2021/248005A1 |
Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates (ADCs) such as those comprising a splicing modulator) that bind to BCMA are disclosed. The disclosure further relates to methods and compositions for u...
|
|
WO/2021/237371A1 |
The present application describes process for preparing an ortho-allylated hydroxy aryl compounds such as compounds of Formula (I) by reacting an allylic alcohol with a hydroxy aryl compound in the presence of aluminum compound selected ...
|
|
WO/2021/241246A1 |
Provided are a radiation-sensitive resin composition capable of exhibiting adequate levels of sensitivity, LWR performance, and CDU performance, and a method for forming a pattern. This radiation-sensitive resin composition contains a so...
|
|
WO/2021/236578A1 |
Chromen-4-one derivatives, such as e.g. flavone derivatives and pharmaceutical compositions thereof are disclosed. In some instances, the compounds have increased aqueous solubility, bioavailability, and ability to cross the blood-brain-...
|
|
WO/2021/235830A1 |
The present invention provides a novel compound, and an organic light-emitting element comprising same.
|
|
WO/2021/233861A1 |
The present invention relates to azabicyclic (thio)amide compounds and the uses thereof for controlling phytopathogenic microorganisms such as phytopathogenic fungi. It also relates to processes and intermediates for preparing these comp...
|
|
WO/2021/234532A1 |
The present invention relates to a pharmaceutical formulation of 5-fluoropyrimidine derivatives or a salt, solvate, or hydrate thereof for oral administration wherein the formulation is a simple composition for ingestion, simple, safest,...
|
|
WO/2021/230653A1 |
The present invention relates to: an anthracene derivative compound having a specific structure; and an organic light-emitting device having low-voltage driving characteristics, comprising same, and also relates to an organic light-emitt...
|
|
WO/2021/231572A1 |
Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, amon...
|
|
WO/2021/226002A1 |
The present disclosure relates to compounds of Formula (I) or Formula (II), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compo...
|
|
WO/2021/218041A1 |
Provided is eribulin and a preparation method for an intermediate thereof. In particular, a compound P1 is prepared by splicing an eribulin fragment A synthesized with diethyl [(naphthylsulfonyl)methyl]phosphonite and a fragment ERB. The...
|
|
WO/2021/207511A1 |
Compounds according to formula (I), where R is as defined herein, have anti-cancer properties.
|
